// App-Quantinova.ai

3512 : FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized StudyProdige 14 accord 21 (METHEP-2), a unicancer GI trial.

Researchers

Presenter

  • Marc Ychou

Principal Investigators

  • Simon Thezenas

  • Rosine Guimbaud

  • Francois Ghiringhelli

  • Anne Mercier-Blas

  • Laurent Mineur

  • Eric Francois

  • Faiza Khemissa

  • Driffa Moussata

  • Yves Becouarn

  • Philippe Houyau

  • Thomas Aparicio

  • Rene Adam

  • Marie-Pierre Galais

  • Franck Audemar

  • Eric Assenat

  • Trevor Stanbury

  • Olivier Bouche

Medical Centers

  • Montpellier Cancer Institute, Montpellier, France

  • Centre Leon Berard, Lyon, France

  • Institut du Cancer de Montpellier, Montpellier, France

  • University Hospital of Rangueil, Toulouse, France

  • Center Georges-Francois Leclerc, Dijon, France

  • Centre Hospitalier Prive de Saint-Gregoire, Saint-Gregoire, France

  • Radiotherapy and Oncology GI and Liver Unit, Institut Sainte-Catherine, Avignon, France

  • Department of Medical Oncology, Centre Antoine-Lacassagne, Nice, France

  • CH Saint Jean, Perpignan, France

  • CHU de Tours, TOURS, France

  • Institut Bergonie, Bordeaux, France

  • Clinique Claude Bernard, Albi, France

  • Hopital Avicenne, AP-HP, Bobigny, France

  • Centre Hepato-Biliaire, AP-HP, Hopital Paul Brousse, Villejuif, France

  • Centre Francois Baclesse, Caen, France

  • Centre hospitalier Cote Basque, Bayonne, France

  • Department of Medical Oncology, Hopital Saint Eloi, Montpelier, France

  • UNICANCER, Paris, France

  • CHU Robert Debre, Reims, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Secondary liver cancer

  • Solid malignancies

Biomarkers

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Bevacizumab

  • FOLFIRINOX

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

  • Prospective

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved